# A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Source: https://onco.cc/trials/nct04725331/  
OnCo record `nct04725331` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BT-001 run by Transgene, terminated.

## Summary

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04725331 by Transgene, with 31 participants enrolled, started 2021-02-25. Conditions recorded: Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer and Non Small Cell Lung Cancer. Interventions recorded: BT-001 and Pembrolizumab [KEYTRUDA®].

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04725331
- Phase: 1/2
- Setting: A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily Injectable Lymph Nodes of Metastatic/Advanced Solid Tumors.
- Sponsor: Transgene
- Enrolled: 31

## Sources

- ClinicalTrials.gov NCT04725331: https://clinicaltrials.gov/study/NCT04725331

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Merkel cell carcinoma](https://onco.cc/cancers/merkel-cell-carcinoma/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [BT-001](https://onco.cc/drugs/bt-001/)
- companies: [BioInvent International](https://onco.cc/companies/bioinvent-international/), [Transgene](https://onco.cc/companies/transgene/)

---
JSON: https://onco.cc/api/v1/entities/nct04725331.json